多發(fā)性骨髓瘤基因修飾瘤苗誘導體內(nèi)抗腫瘤反應的實驗研究(1)

1、    多發(fā)性骨髓瘤基因修飾瘤苗誘導體內(nèi)抗腫瘤反應的實驗研究(1)    】 本研究目的是評價NOD/SCID小鼠皮下移植瘤模型對多發(fā)性骨髓瘤基因修飾瘤苗引發(fā)體內(nèi)抗腫瘤反應的效果。首先給NOD/SCID小鼠腹腔注射人外周血淋巴細胞以在其體內(nèi)重建人的免疫系統(tǒng)，然后皮下接種-射線滅活的基因修飾骨髓瘤細胞sko-007（表達綠色熒光蛋白或者p53、GM-CSF和B7-1基因），以PBS作為對照，最后植入活sko-007細胞進行攻擊。結果發(fā)現(xiàn)，與對照組相比接種感染腺病毒Ad-p53/GM-CSF/B7-1的sko-007

2、細胞可以明顯抑制移植瘤生長，病理分析顯示移植瘤纖維組織增生伴彌漫性壞死增多，血管增生顯著。免疫組織化學染色顯示瘤灶內(nèi)有人T淋巴細胞浸潤。結論： p53、GM-CSF和B7-1基因修飾的骨髓瘤細胞能夠誘導產(chǎn)生抗腫瘤免疫反應，有可能用于人類多發(fā)性骨髓瘤的免疫治療。 【關鍵詞】 多發(fā)性骨髓瘤Multiple myeloma (MM) remains an incurable malignancy despite advances in chemotherapy. Myeloablative chemotherapy followed by allogeneic or autolo

3、gous hematopoietic stem cell transplantation has increased the incidence of complete remission，but almost all patients achieving complete remission ultimately experience relapse1-3. Because these chemotherapies have only limited value，alternative strategies are needed to solve these problems. Immuno

4、therapy may represent a means of maintaining complete remission.    Based on the fact that myeloma cells contain a multitude of tumor antigens that can effectively stimulate antitumor T cells，several investigators have repor- ted immunotherapeutic approaches via inoculating mye-T

5、his project was supported in part by Chinese National Basic Research and Development Grants 973 (No. 2004CB518801 and No. 2002 CB713804)，Chinese High-Tech Program 863 (No. 2003AA216050) and Chinese National Science Foundation (No.30400189).Corresponding author: WU Chu-Tse (吳祖澤)，Academician of Chines

6、e Academy of Sciences，Professor of Department of Experimental Hematology，Beijing Institute of Radiation Medicine.loma cell lysates，whole myeloma cells or genetically modified myeloma cell vaccines to augment the immunogenicity of myeloma cells. Numerous applications of genes encoding tumor

7、 suppressive proteins，cytokines and costimulatory molecules have been proposed in cancer (including MM) therapy4-7. Although the results of most preclinical investigations carried out in vitro and in mouse models were encouraging，the clinical evaluation is less satisfactory8，9. Further studies found

8、 that rather than the absence of tumor-specific antigen，myeloma cells escape from immune surveillance mainly by down-regulating the expression of costimulatory molecules and inhibiting induction and maturation of dendritic cells (DCs)6，10-11. Hence a combination of immune-stimulating genes should be

9、 more efficient than any single gene. In previous study，we have de-monstrated that whole myeloma cell vaccination co-transferred with human wild-type p53，GM-CSF and B7-1 genes mediated by recombinant adenovirus Ad-p53/GM-CSF/B7-1 induces allologous and autologous specific anti-tumor cytotoxicity in

10、vitro12. In this study we investigated whether the generation of Ad-p53/GM-CSF/B7-1-mediated immunity is protective against subsequent tumor challenge.NOD/SCID mice are the most immunodeficient of the SCID variants，and are the most supportive host for human stem cells13. Most SCID mouse myeloma mode

11、ls have used mouse or human MM cell lines. In 2 studies，fresh BMC from MM patient survived in conventional SCID mice，and in one group it was observed that human MM cell lines colonized in human fetal bone implanted subcutaneously in SCID mice14-16. However，all the mice myeloma models could

12、 not reflect the interaction between human immune system and human myeloma cells.    HuPBL-NOD/SCID mouse model has been applied in several other tumors17-18. In this study，we intraperitoneally injected human PBL into NOD/SCID mice to establish human immune system，innoculated the

13、 animals with genetically modified human myeloma cell vaccine，and then challenged subcutaneously the mice with live parental myeloma cells. The result showed that p53，GM-CSF and B7-1 gene-modified myeloma cell vaccine produces an in vivo antitumor immune response.Materials and MethodsAnimals，myeloma

14、 cells and peripheral blood lymphocytes (PBL)In vivo experiments were performed in female NOD/SCID mice (from the Experimental Animal Center，Chinese Academy of Medical Sciences，Beijing)，aged 7 to 9 weeks，which were bred and maintained in specific pathogen-free conditions.    In t

15、his study，a human myeloma cell line sko-007，with human leukocyte antigen (HLA) A2 positive，was kindly provided by Professor Bei-Fen SHEN from Beijing Institute of Basic Medical Sciences and was cultured in RPMI 1640 (Sigma) supplemented with 10% FBS，100 U/ml penicillin，and 100 g/ml streptomycin.

16、0;   PBLs of normal donors in the Beitaiping Road 2# Hospital of Beijing，China，applied for establishment of human immune system in NOD/SCID mice，were isolated by Ficoll-Paque separation as described previously. Since sko-007 cells are HLA-A2 positive，PBLs with the same HLA antigen wer

17、e selected and cultured in RPMI 1640 containing 15% FBS，5% human AB sera，50 U/ml IL-2，100 U/ml penicillin，and 100 g /ml streptomycin. Cells were maintained in a humidified atmosphere containing 5% CO2 at 37. HLA-A2 gene of PBLs was amplified by polymerase chain reaction (PCR) as described previously

18、19. Briefly，genomic DNA was extracted from PBLs of normal donors according to Wizard genomic DNA purification system (Promega，Madison，WI)，and HLA-A2 PCR was performed in a final volume of 50 l with the use of 500 ng DNA，0.1 nmol/L MgCl2，0.01 nmol/L dNTP，0.01 nmol/L each primer，and 1 U Taq Polymerase

19、 (Promega) in PCR buffer. Five cycles，each consisting of 60 seconds at 96，60 seconds at 66，and 120 seconds at 72，followed by 25 cycles，each consisting of 60 seconds at 96，60 seconds at 56，and 120 seconds at 72，were performed in a Marstercycler Personal DNA Thermocycler (Eppendorf，Hamburg，Germany). T

20、he primers for HLA-A2 amplification were 5-CCTCGTCCCCAGGCTCT-3 (sense) and 5-TGGCCCCTGGTACCCGT-3 (antisense). -actin was used as internal standard. The reaction products were electrophoretically separated through a 1.5% agarose gel and stained with ethidium bromide. The expected products generated b

21、y PCR were 813 base pairs (bp) and 396 bp for HLA-A2 and -actin，respecti-vely.            作者：任素萍，王立生，郭強，王華，賈向旭，徐娟，王恒湘，吳祖澤【摘】本研究目的是評價NOD/SCID小鼠皮下移植瘤模         本篇論文是由3COME文檔頻道的網(wǎng)友為您在網(wǎng)絡上收集整理餅投稿至本站的，論文版權屬原作

22、者，請不用于商業(yè)用途或者抄襲，僅供參考學習之用，否者后果自負，如果此文侵犯您的合法權益，請聯(lián)系我們。Recombinant adenovirus and gene transferAd-GFP (recombinant adenovirus expressing green fluorescence protein) was kindly provided by the Gene Therapy Unit，Baxter Healthcare Corp.，USA. Ad-p53/GM-CSF/B7-1 (recombinant adenovirus coexpressing human wild

23、-type p53，GM-CSF and B7-1 proteins) was constructed by our department via homologous recombination in HEK293 cells (Ads E1-transformed human embryonal kidney cells). The inserted human wild-type B7-1 gene was driven by a Rous sarcoma virus (RSV) promoter，and p53 and GM-CSF genes，linked by internal r

24、ibosome entry site (IRES)，were driven by a cytomegalovirus (CMV) promo-ter20. These two kinds of recombinant adenovirus with high titer and purity were obtained by large-scale amplification in HEK293 cells and ultra-centrifugation in CsCl density gradient solution. The infection titers of Ad-GFP and

25、 Ad-p53/GM-CSF/B7-1 used in this study were 1×1011 pfu/ml and 5×1010 pfu/ml respectively.    To produce the myeloma cell vaccine，sko-007 cells were infected with Ad-GFP or Ad-p53/GM-CSF/B7-1 at a multiplicity of infection (MOI) of 200 for 2 hours. Culture medi

26、um was used for mock infection. After an additional 48 hours incubation at 37，5% CO2，transgenic expression of GFP，as well as B7-1，GM-CSF and p53 mediated by adenovirus were determined by flow cytometry，ELISA and Western blot，respectively，as previous described12.Establishment of human immune system a

27、nd vaccine administrationEighteen NOD/SCID mice were injected intraperitoneally with (3-4)×107 HLA-A2 PBLs in 0.5 ml PBS，pH 7.4 on day 0 and then were randomly divided into 3 groups: control，Ad-GFP and Ad-p53/GM-CSF/B7-1 group. Each group of 6 huPBL-NOD/SCID mice was immunized twice subcutaneou

28、sly on the abdomen with 1 ×106 irradiated Ad-p53/GM-CSF/B7-1- or Ad-GFP-infected sko-007 cells in 0.2 ml PBS or 0.2 ml PBS on days 7 and 14. Following vaccination，all animals received subcutaneous injection of 500 U recombinant human IL-2 per mouse for 3 times a week until s

29、acrificed.Tumor-challenge studiesOn day 7 after the second injection，various treatment groups of mice were challenged subcutaneously on their backs with 5 × 106 live sko-007 cells. Tumor growth was monitored 2 to 3 times a week by measuring 2 maximum diameters of the tumor at the site of challe

30、nge with a vernier caliper and was reported as a mean of the 2 diameters. Mice were weighed using an electric scale and sacrificed by eyeball extirpation on day 66. The tumors were excised and weighed. The tumor volume was determined by measuring the length (a)，width (b) and thickness (c) using a ve

31、rnier caliper and calculated by the formula: abc/6(mm2). The weight index was calculated as the weight ratio of tumor / mouse.Processing of specimens for histopathologyWhen mice were killed，tumor tissues were removed from various treatment groups and fixed in 10% phosphate-buffered formalin for 24 t

32、o 48 hours，processed through graded alcohols，and embedded in paraffin. Serial sections of tumors were cut at various levels and stained with hematoxylin and eosin for histopathologic analysis. Additional sections were used for immunohistochemical staining for human T lymphocytes using monoclonal rab

33、bit anti-human CD3 antibody (Zhongshan，Beijing). Subsequently，tissues were incubated with polyclonal biotin-conjugated goat anti-rabbit antibody (Zhongshan) followed by streptavidin- horseradish peroxidase (Zhongshan). The staining reaction was performed for 10 min with 3，3-diamino-benzidine-tetrahy

34、drochloride (Zhongshan) in PBS (60 mg/100 ml). Finally，the tumor tissues were stained with hematoxylin to display the caryons.Determination of human Ig levelsLevels of human IgG and IgA in the sera of huPBL-NOD/SCID mice were determined by agar diffusion assay. When mice were sacrificed，peripheral b

35、lood was harvested by eyeball extirpation. 100 l sera were aspirated following centrifugation and mixed with 300 l distilled water. 10 l mixture of each sample was added to the assay hole of agar diffusion plate. After 24 hours incubation at room temperature，diameter of assay ring was tested and the

36、 content of human IgG or IgA was obtained according to standard curve.Flow cytometry of human cells in mice spleensWhen mice were sacrificed，spleens were removed and homogenized into a single-cell suspension. The spleen cells were washed twice in PBS，labeled with CD45-fluorescein isothiocy

37、anate (FITC) (Becton Dickinson Bioscience PharMingen) for 30 min at 4°C，treated with 1×FACS Lysing solution (Becton Dickinson) for additional 15 minutes to lyse erythrocytes，and then washed twice before analysis. Cell surface immunofluorescence was measured using a FACSCalibur flow cytomet

38、er (Becton Dickinson Biosciences) and was analyzed with CellQuest software (Becton Dickinson Biosciences).Statistical analysisAll data were presented as mean ± SD. SAS software (SAS，USA) was employed to determine the statistical significance of differences in weight index between samples using

39、ANOVA analysis and DUNNETT t test，and P<0.05 was accepted as indicating significance.            作者：任素萍，王立生，郭強，王華，賈向旭，徐娟，王恒湘，吳祖澤【摘】本研究目的是評價NOD/SCID小鼠皮下移植瘤模         本篇論文是由3COME文檔頻道的網(wǎng)友為您在網(wǎng)絡上收集整理餅投稿至本

40、站的，論文版權屬原作者，請不用于商業(yè)用途或者抄襲，僅供參考學習之用，否者后果自負，如果此文侵犯您的合法權益，請聯(lián)系我們。     ResultsDiscrimination of HLA-A2 PBLs and reconstruction of human immune system in NOD/SCID miceTo efficiently present tumor antigens of HLA-A2 positive sko-007 cells，PBLs from HLA-A2 normal donors were discriminated

41、. As shown in Figure 1，3 of 6 DNA samples of PBLs were HLA-A2 positive，confirmed by PCR amplification. These PBLs from 3 donors were then inoculated to establish human immune system in 18 NOD/SCID mice by intraperitoneal injection.    To testify the availability of the huPBL-NOD/

42、SCID mice model，human Igs in the sera and human leukocytes in the spleens were determined at the time when animals were sacrificed. Human IgG contents in control，Ad-GFP or Ad-p53/GM-CSF/B7-1 group were 5.73±3.14 g/L，5.42±2.11 g/L or 8.41±521 g/L，respectively (P>

43、0.05)，and IgA contents were 1.29±0.30 g/L，1.39±0.46 g/L or 1.61±0.70 g/L，respectively (P>0.05). Human leukocytes were found in the spleens of mice (Figure 2). Our data indicated that human immune system was successfully established in NOD/SCID mice.High expression of tran

44、sgenes in sko-007 cellsApplying GFP as the reporter gene，several research groups，including us，have demonstrated efficient adenovirus-mediated gene transfer into myeloma cells. At a MOI of 200 pfu/cell，nearly all sko-007 cells were GFP-positive without obvious adenoviral toxicity (Figure 3A). Our pre

45、vious study further indicated that human wild-type p53，GM-CSF，and B7-1 genes media- ted by the recombinant adenovirus Ad-p53/GM-CSF/B7-1 were highly expressed in three MM cell lines (sko-007，U266 and RPMI8226) and primary myeloma cells，and that Ad-p53/GM-CSF/B7-1 had growth-    i

46、nhibiting and apoptosis-inducing as well as immunogenicity-enhancing effect on myeloma cells12. In this study，we chose sko-007 to produce gene-modified MM vaccine and transplanted tumor in huPBL-NOD/SCID mice model. As shown in Figure 3B-D，the expressions of B7-1，GM-CSF and p53 on Ad-p53/GM-CSF/B7-1

47、-infected sko-007 cells were determined by flow cytometry，ELISA and Western blot.Generation of Ad-p53/GM-CSF/B7-1-mediated immunity is protective against subsequent tumor challengeTo examine whether the MM vaccine might affect its antitumor immunity in vivo，huPBL-NOD/SCID mice receiving 2 consecutiv

48、e injections of irradiated (30 Gy) Ad-GFP- or Ad-p53/GM-CSF/B7-1-infected sko-007 cells or PBS were challenged with 5 ×106 sko-007 live tumor cells at day 7 after the second injection. Tumor growth was followed at the injection site. There were no differences between 3 group

49、s within 40 days after tumor cell injection. At the time of sacrifice，most animals in control or Ad-GFP group (4 of 6 mice with PBS and 5 of 6 mice with Ad-GFP-infected sko-007，respectively) developed massive local tumors. In contrast，only 3 of 6 animals injected with Ad-p53/GM-CSF/B7-1-tr

50、ansferred sko-007 cells had measura-ble tumors (Figure 4). SAS analysis of the tumor weight index showed that Ad-p53/GM-CSF/B7-1-infected sko-007 vaccination significantly reduced tumor growth，compared with controls receiving Ad-GFP modified tumor cells or PBS (P<0.05 and P<0001，resp

51、ectively) (Figure 4).    The in vivo antitumor activity of Ad-p53/GM-CSF/B7-1- transferred sko-007 cells was further stu-died by histopathologic analysis of implanted tumors of 3 groups. In PBS group，tumor cells were eugonic and showed typical morphologic features of neoplastic p

52、lasma cells，ie，irregular nuclear profiles with priminent nucleoli and abundant cytoplasma. Sheet necrotic areas were also identified (Figure 5A). Otherwise，in Ad-p53/GM-CSF/B7-1 group，tumor tissues displayed diffuse necrosis，mainly caused by apoptosis，accompanied with significant fibroplasias and bl

53、ood vessel hyperplasia (Figure 5C). Tumor tissues of Ad-GFP group were similar to those of PBS group，accompanied with various degree of fibroplasias (Figure 5B). The results indicated that vaccination of mice with Ad-p53/GM-CSF/B7-1-transferred sko-007 cells displayed enhanced immunological protecti

54、on compared to mice vaccinated with Ad-GFP- transferred sko-007 cell or PBS only. Immunostaining showed infiltration of human T cells in the tumor tissues，especially in the mice receiving Ad-p53/GM-CSF/B7-1-transferred sko-007 vaccination (Figure 6).DiscussionVaccination with whole tumor c

55、ells represents an attractive strategy for human cancer immunotherapy. Human tumors are extremely heterogeneous，making the identification of one or more universal tumor antigens extremely difficult for many tumors. In addition，many potential tumor-associated antigens have not been  &#

56、160;  Transgenic expression of costimulatory molecules and/or cytokines is one means of enhancing the im-mune response to whole tumor cells. B7-1 and GM-CSF are particularly attractive for the immunotherapy of MM. It has been demonstrated in previous studies that myeloma cells lack the cos

57、timulatory molecule B7-1 and maturation of dendritic cells (DCs) is inhibited in MM patient，which thus may fail to induce an effective antitumor T-cell response6，10. Additionally，recent studies have shown that GM-CSF has the ability to promote maturation of precursor cells into DCs，and DCs cultured

58、with apoptotic bodies stimulated significantly greater T cell proliferation than MM lysate-plused DCs or MM cells alone. Mature DCs then generate tumor antigen epitopes for cross-presentation on HLA-I class to stimulate CD8 cytocoxic T cells，or for conventional presentation on HLA-II class

59、 to stimulate CD4 helper T cells10，21，22. Considering that over-expression of exogenious P53 protein could induce apoptosis of p53 positive or negative myeloma cells，we proposed a new approach of co-transfer of immunomodulatory genes GM-CSF and B7-1 and apoptosis-inducing gene p53 to plasm

60、a cells as tumor vaccine might invoke an autologous immune response to tumor cells. Preliminary research suggested that by the introduction of wild-type p53，GM-CSF and B7-1 genes mediated by recombinant adenovirus Ad-p53/GM-CSF/B7-1，the growth of MM cells was inhibited via enhanced apoptosis and sig

61、nificant proliferation of autologous peripheral blood lymphocytes and specific cytotoxicity against autologous primary MM cells were induced in vitro12.            作者：任素萍，王立生，郭強，王華，賈向旭，徐娟，王恒湘，吳祖澤【摘】本研究目的是評價NOD/SCID小鼠皮下移植瘤模         本篇論文是由3COME文檔頻道的網(wǎng)友為您在網(wǎng)絡上收集整理餅投稿至本站的，論文版權屬原作者，請不用于商業(yè)用途或者抄襲，僅供參考學習之用，否者后果自負，如果此文侵犯您的合法權益，請聯(lián)系我們。    In this report，we have